417JC, Clinical Scientist, Clinical Development

Job Code 417JC


Fate Therapeutics is seeking an experienced, independent and highly motivated clinical scientist professional. The successful candidate will be a member of the clinical development team, working closely with both the clinical and research groups (medical monitor, statistician, regulatory, translational research) to support and deliver clinical development strategies. The position contributes to the trial development strategy and execution, assisting with protocol development, study design and clinical study supporting functions. The successful candidate will be familiar with current approaches regarding oncology treatment modalities, drug mechanism of action, approaches to drug development, and regulatory and operational requirements. The ideal candidate should have experience in solid tumor oncology, with experience in the design and conduct of clinical studies in this therapeutic area. Experience with cellular therapies is desirable. The position reports to the VP, Clinical Development and is based at the Company’s corporate headquarters in San Diego, California or remotely from the San Francisco, California area.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 417JC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.